Strategic Expansion Growth in RWE/HEOR and market access services with recent executive hires and new platforms signals opportunities to cross-sell integrated evidence generation, payer engagement, and access strategy services to life science partners seeking end-to-end solutions.

New Platform Launch The launch of the EVID AI evidence synthesis platform and free access through 2026 presents a door to data-driven partnerships and collaboration, enabling prospecting of sponsored research, joint analyses, and pilot programs with approved organizations.

Leadership Momentum Recent appointments at EVP level in RWE/HEOR and Access & Pricing indicate a strategic emphasis on payer insights, pricing strategies, and value demonstration, creating opportunities to engage at the executive level with comprehensive market access proposals.

US Market Focus Enhanced US market access analytics and a US-centric data analytics push suggest potential to partner with US-based biopharma and med device clients for real-world evidence generation, HTA support, and payer negotiations.

Tech-Enabled Differentiation A tech-enabled engagement model leveraging RPR insights and a modern tech stack (AWS, Salesforce, Smartsheet) positions Genesis to propose scalable, automated evidence generation and stakeholder insights solutions to accelerate partner timelines.